The PRP used to produce these exosomes was prepared from whole blood donated by healthy human volunteers.  
  

Researchers found that PRP-derived exosomes increased proliferation and migration of hair-follicle stem cells, reduced apoptosis under oxidative stress, and restored markers of pluripotency (SOX2, OCT4) and follicular identity (CD34, K15). In C57BL/6 mice, repeated subcutaneous injections led to faster hair regrowth within 14 days, with a higher number of follicles in the growth phase and thicker dermal layers on histological analysis.  

Mechanistically, the study showed that PRP-exosomes upregulated SIRT1, a key longevity regulator, which deacetylated the transcription factor FoxO3a, activating antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT). This pathway helped counter oxidative stress – a known factor in hair loss – and supported follicle regeneration.  

Although these findings remain preclinical, they add to evidence that PRP-derived exosomes could represent an evolution of traditional PRP therapy by concentrating and refining its regenerative components. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) permits the use of PRP where it is autologous – prepared and re-injected for the same patient during a single treatment session – but allogeneic or donor-derived PRP products remain outside the current regulatory framework.